Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBITDA Margin (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of EBITDA Margin data on record, last reported at 760.0% in Q4 2025.

  • For Q4 2025, EBITDA Margin changed N/A year-over-year to 760.0%; the TTM value through Dec 2025 reached 167.98%, changed N/A, while the annual FY2025 figure was 156.28%, 840628.0% down from the prior year.
  • EBITDA Margin reached 760.0% in Q4 2025 per RCUS's latest filing, down from 435.71% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 143.84% in Q3 2024 and bottomed at 824.66% in Q3 2021.
  • Average EBITDA Margin over 5 years is 352.06%, with a median of 289.88% recorded in 2023.
  • The widest YoY moves for EBITDA Margin: up 178044bps in 2021, down -82738bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 78.45% in 2021, then crashed by -382bps to 221.19% in 2022, then plummeted by -33bps to 293.55% in 2023, then soared by 149bps to 143.84% in 2024, then tumbled by -628bps to 760.0% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 760.0% in Q4 2025, 435.71% in Q1 2025, and 143.84% in Q3 2024.